Novel Biomarkers Related Xuebijing Injection Improves Sepsis

Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, posing a serious threat to human health. The study demonstrated that hemopexin injection significantly reduced the 28-day all-cause mortality rate of sepsis patients, and this study clarified the specific target and molecular mechanism of hemopexin injection in the treatment of sepsis, which may be of great scientific significance and clinical value for the precise treatment of sepsis and the research and development of new drugs.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Sepsis Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Systemic Inflammatory Response Syndrome

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Meeting the Sepsis 3.0 diagnostic criteria;
SOFA score ≥ 2 and < 13;
Signed informed consent.

Exclusion criteria

Age <18 years or >75 years;
Pregnant or lactating women;
Presence of severe primary diseases including malignant tumors severe hematologic disorders and HIV infection;
Current use of immunosuppressants or history of organ transplantation within the past 6 months;
Comorbidities that significantly affect vascular endothelial structure and function such as acute myocardial infarction.

Treatment and study plan

Primary outcomes

Single-cell transcriptomic analysis of inflammatory and metabolic gene expression, measured using scRNA-seq, with data summarized as differential expression profiles.

Time frame: Day7

Single-cell transcriptomic analysis of inflammatory and metabolic gene expression, measured using scRNA-seq, with data summarized as differential expression profiles.

Sponsors and collaborators

Lead sponsor

Southeast University, China

Other

Registry information

Official study title

Xuebijing Injection Regulates Endothelial Cell Panapoptosis in Treating Sepsis Through PCDHAC2/BAX/AIM2 Pathway

Important dates

Study start: 2025
Primary completion: 2028
Study completion: 2028
First posted: Apr 9, 2025
Registry last updated: Apr 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting